Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.63 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14547780 | 0.85 | ALDH1A1 (0.60) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL1784315 | 0.84 | ALDH1A1 (0.63) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL10753064 | 0.84 | CHRNB2 (0.58) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL2720213 | 0.83 | ALDH1A1 (0.64) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL20902856 | 0.83 | LMNA (0.58) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL2720215 | 0.83 | ALDH1A1 (0.64) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL8977175 | 0.82 | ALDH1A1 (0.73) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL217722 | 0.82 | LMNA (0.57) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL7778609 | 0.82 | ALDH1A1 (0.66) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL15272157 | 0.81 | HPGD (0.59) | KMT2AMEN1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281446-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | RIGEL PHARMACEUTICALS, INC. | 2013-10-24 | — | — | US | disclosed |
| US-8486935-B2 | Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]2,4-pyrimidinediamine | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130102596-A1 | METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO [1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3- (METHYLAMINOCARBONYLMETHYLENEOXY) PHENYL]2,4-PYRIMIDINEDIAMINE | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013059631-A1 | METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO [1,4] OXAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3- (METHYLAMINOCARBONYLMETHYLENEOXY) PHENYL] 2,4-PYRIMIDINEDIAMINE | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20120316160-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | RIGEL PHARMACEUTICALS, INC. | 2012-12-13 | — | — | US | disclosed |
| US-8193181-B2 | Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine | RIGEL PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193181-B2 | Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine | RIGEL PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100204232-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZ0 [1,4] OXAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3-(METHYLAMINOCAR BONYLMETHYLENEOXY) PHENYL] 2,4-PYRIMIDINEDIAMINE | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
| US-20100204232-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZ0 [1,4] OXAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3-(METHYLAMINOCAR BONYLMETHYLENEOXY) PHENYL] 2,4-PYRIMIDINEDIAMINE | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
| WO-2009031011-A2 | XINAFOATE SALT OF N4-(2, 2-DIFLUORO-4H-BENZ0 [1,4] 0XAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3- (METHYLAMINOCAR BONYLMETHYLENEOXY) PHENYL] 2, 4-PYRIMIDINEDIAMINE | PFIZER LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008024634-A1 | PYRIMDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007042299-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204232-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZ0 [1,4] OXAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3-(METHYLAMINOCAR BONYLMETHYLENEOXY) PHENYL] 2,4-PYRIMIDINEDIAMINE | HRH4, P2RY10, KCNN4 | KMT2A 690/4885MEN1 3005/4885ALDH1A1 1277/4885 |
| US-20120316160-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | P2RY4, KCNN4, KCNJ4 | KMT2A 953/4885MEN1 3663/4885ALDH1A1 941/4885 |
| US-20130102596-A1 | METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO [1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3- (METHYLAMINOCARBONYLMETHYLENEOXY) PHENYL]2,4-PYRIMIDINEDIAMINE | YTHDF1, YTHDF2, YTHDF3 | KMT2A 1105/4885MEN1 2883/4885ALDH1A1 1354/4885 |
| US-20130281446-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | P2RY4, KCNN4, KCNJ4 | KMT2A 953/4885MEN1 3663/4885ALDH1A1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.